- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/74 - Major histocompatibility complex [MHC]
Patent holdings for IPC class C07K 14/74
Total number of patents in this class: 1971
10-year publication summary
|
77
|
90
|
113
|
173
|
225
|
229
|
278
|
241
|
203
|
146
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1158 |
526 |
| Cue Biopharma, Inc. | 187 |
95 |
| Regeneron Pharmaceuticals, Inc. | 4426 |
59 |
| CRISPR Therapeutics AG | 373 |
55 |
| University Health Network | 1052 |
29 |
| 10X Genomics, Inc. | 1270 |
23 |
| The Regents of the University of California | 20268 |
19 |
| Board of Regents, The University of Texas System | 5927 |
18 |
| Imcyse SA | 73 |
15 |
| Universite de Montreal | 346 |
15 |
| Sangamo Therapeutics, Inc. | 419 |
15 |
| Sana Biotechnology, Inc. | 162 |
15 |
| Ecole Polytechnique Federale de Lausanne (epfl) | 1563 |
14 |
| Oregon Health & Science University | 766 |
14 |
| Inscripta, Inc., FORMERLY Muse Biotechnology, Inc. | 284 |
13 |
| UTi Limited Partnership | 455 |
12 |
| President and Fellows of Harvard College | 6030 |
11 |
| Dana-Farber Cancer Institute, Inc. | 2621 |
11 |
| Immunocore Limited | 224 |
11 |
| Xyphos Biosciences Inc. | 35 |
11 |
| Other owners | 990 |